illumina result foreshadow growth margin
benefit
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim apr
price data apr
rate updat apr
currenc amount express
valuat growth profit
methodolog valu compani
current hands-down leader genom sequenc illumina
face impress growth opportun emerg
technolog creat new research applic also
demand product sustain rel high
technolog advanc sequenc industri
brought cost assembl one genom nearli
billion year complet human genom project
almost matter day follow
announc illumina highseq earli
innov continu push cost enhanc
access technolog number sequenc
whole human genom like hundr thousand
also see plenti opportun increas demand especi
oncolog reproduct health estim genom
growth demand genom sequenc place
clear winner time
solid-phas amplif fluoresc label sequencing-by-synthesi
technolog support one versatil platform
cost turnaround time read length throughput error
rate -- squash current competit also offer
strong assort sampl prepar post-run data
analysi tool includ open-sourc cloud-bas data
storag genom assembl softwar
near term think continu leadership
threat disrupt technolog remain concern
on-going improv compani flow cell densiti
chemistri process camera speed support
throughput cost improv emerg
technolog made big promis unconvinc
emerg system dethron
meantim pursu innov method includ
nanopor chip-bas detect devic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
major player life scienc tool analyz genet materi
revenu microarray genom sequenc machin
dispos make compani revenu approxim
compani sale come sequenc servic essenti
growth stem compani genom sequenc
product includ compani high-throughput novaseq hiseq
instrument addit benchtop nextseq miseq miniseq
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
illumina result foreshadow growth margin
benefit jan
thank earn preview outlook
earlier year compani fourth-quart result held
major surpris although rais fair valu
estim per share consid share bit
overvalu acknowledg firm possess
impress growth outlook thank opportun
instrument upgrad increas demand sequenc
research clinic applic penetr
prenat screen oncolog panel consumer-
orient genet test think like
surpass revenu growth
adjust ep target larg base healthi
demand new exist custom newer
novaseq product line genom sequenc field
remain potenti disrupt area long term
narrow-moat still face littl competit
moment thank firm consist innov
novaseq placement
effici back half year product
launch help push sequenc instrument growth
drove gross margin expans approxim
basi point product mix shift higher-margin
consum also help boost profit
sequenc consum advanc nearli
quarter dynam continu uphold growth
expand profit
product launch continu expand pie
sequenc market manag expect ship
novaseq translat
million equip sale base
novaseq order come new custom
mostli line expect previou product
launch weve seen iseq launch
year slower ramp given focu clinic
market lower price point afford price
attract new custom platform
potenti upgrad futur
valuat growth profit jan
rais fair valu estim
per share increas growth forecast
follow recent result higher expect
instrument placement particular novaseq
product line think maintain nearli
averag revenu growth rate next five year thank
healthi demand sequenc technolog despit
concern competit pressur clinic diagnost
market macroeconom condit
assum sustain revenu growth
peer thank on-going strength research market
well grow adopt sequenc technolog
among clinic custom repres consider
global
macroeconom concern especi europ japan
still anticip research budget continu
priorit genom sequenc spend due research
advanc technolog provid clinic
diagnost market remain larg opportun illumina
sinc sequenc potenti disrupt segment
older diagnost test addit creat new test
avenu liquid biopsi screen test
compani pursu grail ventur cancer panel
companion diagnost prenat screen repres
near-term clinic growth opportun ultim
pace growth market remain somewhat uncertain
due resourc constraint regulatori issu
reimburs hurdl among clinic custom base
meanwhil expect flat sale smaller
microarray segment higher volum help off-set price
invest new busi ventur like helix
reduc near-term profit despit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
competit greater oper leverag could boost
valu reach nearli scenario return
capit
fair valu approxim model slower
penetr genom sequenc technolog
competit emerg platform particularli
benchtop market lead averag annual growth near
oper margin remain
manag difficulti scale
busi
competit increas price pressur recent ventur
lead higher on-going cost return capit remain
high-teen scenario assum highli
success technolog enter field caus illumina
lose meaning market share high-throughput
benchtop portion market think share would
worth remot disrupt case
long-term growth return capit assumpt
young compani emerg market
potenti disrupt technolog believ
rel high barrier entri rise switch cost
unmatch pace innov support
econom profit next decad even though risk
emerg technolog horizon largest
concern moat opinion current view
threat major disrupt technolog remot
current domin genom sequenc
market instrument versatil low oper cost
high throughput accuraci turnaround speed faster
simpler sampl prepar support data analysi
softwar make drive forc behind compani
market share market share nearli
grow base estim howev owe
benefit rise higher-margin consum
instal base instrument despit higher research
develop spend ventur combin
increas salesforc requir clinic diagnost
market think opportun greater oper
leverag exist long term
product test come market clinic market
penetr increas project culmin
adjust oper margin averag return
invest capit estim illumina cost
equiti
give high uncertainti rate due
compani product concentr genom sequenc
market combin potenti disrupt entrant
highli technolog field
bull-cas scenario project faster market
adopt genom sequenc greater market share
gain less pressur compet sequenc
technolog support annual revenu growth
next sever year also assum less
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
compani essenti monopoli high-throughput
portion market sequenc genet
materi probabl come machin
face competit benchtop segment smaller
lab clinic applic thermo fisher
previous life technolog ion torrent platform
think barrier entri high genom sequenc
thank intersect three highli technic
instrument
complex data analysi -- requir read genet
inform ventur capit still easili flow
nascent market get actual product market
prove extrem difficult numer contend
includ like sequenc techniqu nearli
alway emerg small-scal method develop
major research univers manufactur scalabl
develop molecular enzym need process
amplifi genet materi microfluid engin
complex softwar algorithm assembl massiv
amount data support custom servic creat
custom switch cost slowli rise
sequenc market opinion becom
wide adopt platform custom orient around
prepar method studi protocol clia
certif support industri
public difficult hurdl competitor quickli
overcom think factor becom even
import genom sequenc becom access
smaller research clinic laboratori possess less
technic expertis fewer resourc next
year food drug administr like becom
increasingli involv regul rise sequenc
technolog clinic diagnost market
requir evid accuraci reliabl back
publish research illumina miseq first
fda-approv genom sequenc instrument
market addit regulatori mileston come
near futur exampl manag discuss
agenc fda-approv oncolog panel specif
instrument manag hope enrol larg
clinic trial cancer screen test
imagin industry-lead innov
continu keep compani step ahead competitor
especi larger high-throughput market thank
addit advanc flow cell densiti read length
boost throughput along faster camera chemistri
process improv sequenc cycl time think
devic continu lead industri
sequenc cost speed throughput also
sampl prepar
technolog cloud-bas data storag
possess nearli issu pend patent
technolog
admit threat emerg sequenc
platform could derail trajectori think firm
domin high-throughput market expect
limit new technolog on-going
innov capit alloc preserv
compani growth opportun return capit due
high threshold competitor directli blunt illumina
essenti monopoli high-throughput portion
market dont envis threat segment
near futur sale high-throughput hiseq
machin compos nearli compani sale
estim think there risk
benchtop market base knowledg emerg
technolog skeptic competitor could
make seriou inroad next year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
award stabl moat trend dont see
signific near-term threat exist platform
market nearli guarante illumina
leadership next year meanwhil illumina
continu research innov genom sequenc
method includ nanopor chip-bas detect
method plan chip-bas detect
machin avail market late
exist platform continu struggl scale
platform inher technolog limit
give competit edg next year
roch recent announc discontinu
sequenc platform pyrosequenc technolog
struggl high error rate could keep pace
industri throughput addit seem thermo fisher
previous life technolog ion torrent platform
reach upper bound read densiti detect
limit chip technolog despit initi appeal
low reagent cost non-opt platform
meanwhil read length limit long run time
requir essenti render life technolog
thermo fisher previou solid platform obsolet
pacif bioscienc first success third-gener
whole molecul sequenc technolog probabl never
compet high-throughput platform like
carv small nich market platform
long read capabl help microbi
genom de novo analysi lack refer dna
awar multipl venture-back technolog -- rang
nanopor electron microscopi -- present low
extrem low probabl success view
current nanopor technolog view mani
next possibl evolut sequenc method thank
impress list promis includ littl sampl
prepar dna amplif need expens
reagent label long read length fast run time
greatli simplifi sequenc assembl data
analysi current oxford nanopor appear possibl
closest market technolog measur
charg differenti dna strand pass
nanopor best oxford first minion devic
minor competit threat benchtop instrument
segment opinion oxford potenti higher
throughput instrument would direct threat
seem potenti year away enter
market guess similar pacif bioscienc
real-tim process detect accuraci appear issu
oxford nanopor lead rel high error rate
compani face delay meet product
launch goal base cursori analysi limit
knowledg oxford technolog think compani
greater threat nich player like
time meanwhil instrument alreadi
push sequenc cost par initi rumor
oxford capabl base calcul illumina
initi investor oxford nanopor held
minor stake compani late
rest laurel unlik mani compani
announc technolog advanc
histori hold technolog develop close vest
announc new technolog readi
advanc industri difficult specul
continu aggress use capit resourc
pursuit improv exist technolog well
novel sequenc approach addit
earli investor oxford nanopor instanc
licens anoth nanopor technolog late
possibl simultan develop
in-hous nanopor devic time left
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
behind roch purchas early-stag nanopor
technolog acquisit strato genia
bio-rad purchas gnubio
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market repres larg growth opportun
leapfrog platform lead market share
oweak econom condit constrain global
research budget academ govern
commerci market specif priorit
oa signific portion market growth
requir clinic adopt sequenc technolog
face consider regul valid
treatment guidelin reimburs challeng
current largest grow
instal base sequenc instrument
on-going sale higher-margin
futur success depend manag
abil sustain innov astut capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
think solid financi health thank
strong balanc sheet larg influx recur revenu
consum instal base sequenc
machin decemb possess nearli
billion cash invest compar
convert debt gross
debt/ebitda gener remain near time
although cash flow continu rise firm
like continu make invest includ modest
acquisit enhanc competit posit
disrupt technolog new genom sequenc
platform greatest risk view
outpac current sequenc competitor
market name roch thermo fisher previous life
technolog pacif bioscienc ventur
capit continu fund third-gener technolog
could eventu threaten leadership
sequenc market despit rapid pace
innov consider research develop
shift toward technolog could elimin need
complic microfluid system fluoresc reagent
time-consum sampl prepar camera laser
besid potenti lower-cost faster simpler
use third-gener technolog could also greatli
increas read length suggest easier align
sequenc less complic data manag
softwar program awar multipl ventur
develop new sequenc technolog current
state advanc difficult determin think
technolog earli phase develop
suggest littl threat near term
howev platform nanopor shown
potenti promis earli publish literatur numer
promis sequenc technolog fail
howev includ helico point
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
emerg technolog remain larg untest
like face numer develop challeng
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
assign exemplari stewardship rate
base compani histori shrewd capit alloc
manag face tall order quest sustain
blister pace
develop
field potenti disrupt
technolog one seriou misstep failur acquir
long-term success manag team
like cogniz threat anyon els
howev think excel drive industri
innov pick winner capit deploy
va collegeamerica growth fund america
share
fund
share
fund
view innov high research
develop spend combin prescient
well-tim acquisit upheld impress growth
return capit domin sequenc
market larg stem acquisit solexa
gave foundat fluoresc
label termin sequencing-by-synthesi chemistri
sequenc machin recent acquisit
includ epicent technolog nextbio moleculo
address platform weak
acquisit includ bluegnom verinata
help lay groundwork growth
diagnost manag hope recent busi
ventur helix grail improv compani access
clinic test market
leadership push sequenc innov curv
also build sampl prep data analysi
posit prefer sequenc platform
franci desouza replac jay flatley ceo juli
desouza join compani presid
execut experi symantec addit cofound
number technolog compani despit recent
growth challeng late earli
leadership transit gone fairli smoothli flatley
ceo sinc transit role
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
execut chairman like continu
consider input strateg initi
flatley previous co-founder ceo molecular
dynam sale addit
board director blain bowman lead
independ director board member sinc
compens determin larg revenu
oper incom target perform stock unit
best measur valu creation view
minor quibbl relat compani histor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
illumina result foreshadow growth margin
benefit jan
thank earn preview outlook
earlier year compani fourth-quart result held
major surpris although rais fair valu
estim per share consid share bit
overvalu acknowledg firm possess
impress growth outlook thank opportun
instrument upgrad increas demand sequenc
research clinic applic penetr
prenat screen oncolog panel consumer-
orient genet test think like
surpass revenu growth
adjust ep target larg base healthi
demand new exist custom newer
novaseq product line genom sequenc field
remain potenti disrupt area long term
narrow-moat still face littl competit
moment thank firm consist innov
novaseq placement
effici back half year product
launch help push sequenc instrument growth
drove gross margin expans approxim
basi point product mix shift higher-margin
consum also help boost profit
sequenc consum advanc nearli
quarter dynam continu uphold growth
expand profit
product launch continu expand pie
sequenc market manag expect ship
novaseq translat
million equip sale base
novaseq order come new custom
mostli line expect previou product
launch weve seen iseq launch
year slower ramp given focu clinic
market lower price point afford price
attract new custom platform
potenti upgrad futur
illumina outlin impress novaseq gain
result benefit larg custom stock
order also outlin revenu billion
billion adjust ep
includ slight tax benefit recent law pass
 plan rais fair valu estim
increas growth forecast anticip strong
fourth quarter thank late-year launch
flowcel chemistri high-throughput novaseq
machin sustain momentum throughout
current year exist high-throughput
custom order novaseq despit year
benefit think novaseq upgrad cycl make
difficult sustain impli revenu growth
follow year regardless illumina
growth continu benefit number
market penetr consum genom increas
insur coverag reimburs rate gene
panel companion diagnost prenat test
instrument innov also continu
expand custom base open new sequenc market
disrupt older test method manag
note novaseq order come new
sequenc current desktop lower throughput
previous mention firefli attain
price tag becom compel
clinic market custom updat cartridg use
cmo semiconductor chip dna base detect
improv test volum reduc run time iseq begin
also announc new
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
version flow cell custom like opt
lower cost per sampl higher-throughput
lastli progress novaseq launch associ
consum instal base grow buoy
profit effici manufactur benefici
product mix oper leverag although quarter
adjust oper margin remain last
year margin profit continu
sequenti improv come quarter
ship quarter
post strong earli phase novaseq
plan slightli rais near-term revenu forecast
follow firm third-quart growth
led larg launch progress novaseq product
line enabl compani slightli surpass
year-end expect
capac novaseq line recent launch
higher-throughput flow cell ramp-up custom
consum util drive high growth
plan rais year-end growth forecast
basi point manag rais year-
end ep outlook modestli
previou estim howev anticip
minor increas fair valu estim dont plan
chang long-term growth rate profit
assumpt think narrow econom moat
intact thank firm leadership innov
expect on-going adopt genom sequenc
combin hiseq custom upgrad new
novaseq product line sustain high-teen growth
next quarter especi easier comp
first half although manag note strong
perform nextseq product line attribut
instrument growth consum
growth quarter novaseq backlog
novaseq current system
diminish manag note manufactur
restraint product new-to-sequenc custom
previou benchtop-onli custom compris healthi
one third novaseq order addit
particularli surpris hear manag plan scrap
launch plan lower-throughput novaseq instrument
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
